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Abstract:
The phosphatidylinositol 3-kinase (PI3K) pathway is activated in ~70% of breast cancers. PIK3CA gene mutations or amplifications that affect the PI3K p110α subunit account for activation of this pathway in 20-40% of cases, particularly in estrogen-receptor alpha (ERα)-positive breast cancers. AKT family of kinases, AKT1-3, are the downstream targets of PI3K and these kinases activate ERα. Although several inhibitors of PI3K have been developed, none has proven effective in the clinic, partly due to an incomplete understanding of the selective routing of PI3K signaling to specific AKT isoforms. Accordingly, we investigated in this study the contribution of specific AKT isoforms in connecting PI3K activation to ERα signaling, and we also assessed the utility of using the components of PI3K-AKT isoform-ERα signaling axis as predictive biomarkers of response to PI3K inhibitors. Using a variety of physiologically relevant model systems with defined natural or knock-in PIK3CA mutations and/or PI3K hyperactivation, we show that PIK3CA-E545K mutations (found in ~20% of PIK3CA-mutant breast cancers), but not PIK3CA-H1047R mutations (found in 55% of PIK3CA-mutant breast cancers), preferentially activate AKT1. Our findings argue that AKT1 signaling is needed to respond to estrogen and PI3K inhibitors in breast cancer cells with PIK3CA-E545K mutation, but not in breast cancer cells with other PIK3CA mutations. This study offers evidence that personalizing treatment of ER-positive breast cancers to PI3K inhibitor therapy may benefit from an analysis of PIK3CA-E545K-AKT1-estrogen signaling pathways.
PIK3CA-E545K mutation, which represents 20% of PIK3CA mutations, and PIK3CA-H1047R mutation, which represents 55% of PIK3CA mutations in breast cancer (mycancergenome.org), has similar influence on AKT isoform activation. Exploring these gaps is critical because of recent understanding that AKT isoforms are not functionally similar (13, 14) . Moreover, commonly used constitutively active AKT mutants do not discriminate the functions of different isoforms of AKT (13) . We focused on AKT1 and AKT2 because AKT3 is relevant for only ER-negative breast cancers (15, 16) . Our results showed that, in general, PIK3CA-E545K mutation is associated with AKT1 activation, whereas PI3KCA-H1047R mutation with activation of AKT1, AKT2, or both. AKT1 is essential for ER activity, E2-dependency, and response to PI3K inhibitors in MCF-7 cells with endogenous PIK3CA-E545K mutation. Thus, response of ER-positive breast cancers to PI3K inhibitors may depend on the isoform of AKT activated as a consequence of specific PIK3CA mutation.
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Materials and Methods:
Cell lines: MCF-7, T47-D, LY2, HCC1428, BT-474, SK-BR-3, MDA-MB-231, MDA-MB-436, MDA-MB-468, UACC812, and ZR-75-1 cells were purchased from ATCC.
600MPE cell line was a gift from Dr. Paul Spellman (17) . HCC1428, UACC812 and LY2 cell lines were purchased within last one year and other cell lines have been authenticated within past two years using STR Systems for Cell line identification (DNA Diagnosis Center, Fairfield, OH and Genetica DNA Laboratories, Cincinnati, OH). Human immortalized mammary epithelial cells (HMECs) with targeted replacement of PIK3CA with PIK3CA-E545K and PIK3CA-H1047R were purchased from Horizon Discovery Limited (hTERT-HME1, Cambridge, UK). Drs. Ben Ho Park and Michele Vitolo provided MCF10A cells with targeted PIK3CA mutants and PTEN deletion, respectively (18, 19) . Dr. Alex Toker provided the parental pLKO, AKT1, and AKT2 shRNA lentivirus vectors (20) . Supplementary information has additional details of lentivirus transfection, siRNAs, and cell proliferation assays.
Antibodies: Antibodies against AKT1, AKT2, AKT1_pS473, AKT2_pS474, and phospho-GSK3/ (S9/21) were purchased from Cell Signaling Technology (Danvers, MA). Antibodies against ER, GATA3, GSK3/, FOXA1, cMyc, and Cyclin D1 were purchased from Santa Cruz Biotechnology, whereas AP2 antibody was from Epitomics (Burlingame, CA).
RNA isolation, Microarray, and Quantitative Reverse Transcription Polymerase Chain
Reaction (qRT-PCR): RNA was prepared using RNeasy kit (Qiagen, Valencia, CA) and cDNA from two µgs of RNA was synthesized using the cDNA Synthesis kit (Bio-Rad, Hercules, CA). qRT-PCR was performed using SyberGreen on an Applied Biosystems 7900HT instrument (Applied Biosystems, Carlsbad, CA). Sequences of primers used for qRT-PCR are in Supplementary Table S1 . Microarray with biological triplicates was performed using Illumina HumanHT-12 V4 expression beadchip. Supplementary information contains additional details of microarray data analyses and results have been submitted to Gene Expression Omnibus (GSE60759).
Transcription factor binding site (TFBS) enrichment analyses:
The TFBS enrichment analysis was done using the MotifModeler tool (21) . Briefly, MotifModeler uses array based gene expression data to identify functional binding sites by combining effects of binding sites of different transcription factors and estimating functional effects of predicted motifs under contrasting conditions. The tool makes assumption that differential gene expression is a feature of altered regulation and deduces differentially acting regulatory elements from a dataset of all regulatory elements based upon a list of differentially expressed genes. These binding sites are located within 1000 bases 5' of the transcription start site and in the annotated 3' untranslated region of genes. ER ChIPon-chip data and ChIP-seq data from our previous studies were used to assign ER binding sites (8, 22) .
Analysis of signaling pathways overlap: FOXA1-E2 and PBX1-E2 signatures have been described previously (23) . Gene lists for AKT1 and AKT2 dependent E2-induced genes were imported into Oncomine (24) . Overlap was defined as significant at p value of at 8 least 0.01 and an Odds Ratio 2. Prognostic impact of FOXA1-E2-ER-AKT1 signature was evaluated using two public databases (25, 26) .
Results:
AKT isoform activity in breast cancer cell lines with endogenous PIK3CA
aberrations.
Recently developed antibodies that recognize activated AKT1 (AKT1_pS473) and AKT2 (AKT2_pS474) enabled us to reexamine whether specific isoforms are activated in response to distinct PI3K aberrations. Based on the studies using pan AKT_pS473 antibody, it was suggested that PIK3CA mutation is not always associated with AKT activation. For example, MCF-7 cells with PIK3CA-E545K mutation were reported to lack constitutive AKT activity (27) . In contrast to the results reported using pan AKT_pS473 antibody, AKT1_pS473 was readily detected in MCF-7 cells under serum-deprived and serum-supplemented conditions ( Figure 1A ). AKT1_pS473 and AKT2_pS474 levels (to a lesser extent) in MCF-7 cells under serum-treated condition were higher than in 600MPE cell line, which lacks PIK3CA/PTEN alterations. AKT isoform activity in immortalized breast epithelial cell lines with PIK3CA-E545K or PIK3CA-H1047R mutation. Since PIK3CA-E545K and PIK3CA-H1047R are the most common PIK3CA mutations in breast cancers, we further defined the link between specific PIK3CA mutation and AKT isoform activity using knock-in cell lines.
HMECs and MCF10A cells with targeted replacement of one PIK3CA allele with either E545K or H1047R mutant allele were used (18) . MCF10A cells with homozygous deletion of PTEN were used as a positive control (19) . Under serum-starved condition (24 hours), wild type HMECs displayed residual AKT1 activity, which was significantly higher in E545K and H1047R cells ( Figure 1B ). Under serum and growth factor supplemented condition, mutant cell lines displayed elevated AKT1 activity. Although PIK3CA mutation increased AKT2 activity, the effects were relatively modest. Thus, AKT1 is the major target of PIK3CA mutation in HMEC cells. Increased AKT1 activity in HMEC-E545K and HMEC-H1047R mutant cells correlated with elevated levels of its substrate phospho-GSK3/ ( Figure 1C ).
Results were markedly different in MCF10A derivatives. Basal AKT1_pS473 and AKT2_pS474 levels were similar in serum-deprived parental and mutant MCF10A cells ( Figure 1D ). PTEN deletion and PIK3CA-H1047R mutation but not PIK3CA-E545K mutation resulted in elevated heregulin-induced AKT1_pS473 and AKT2_pS474 levels.
These results indicated that PIK3CA mutations have cell type-specific effects on AKT1_pS473 and AKT2_pS474 levels under basal and/or growth factor stimulated condition. Interestingly, two out of three cell lines with PIK3CA-E545K mutation (HMEC-E545K and MCF-7 but not MCF10A-E545K) but no known growth factor receptor amplification, PTEN loss or K-Ras mutation showed preferential elevation of AKT1_pS473. By contrast, all PIK3CA-H1047R cell lines without growth factor receptor amplification, PTEN loss or K-Ras mutation (HMEC-H1047R, MCF10A-H1047R and T47-D) showed elevated levels of AKT1_pS473, AKT2_pS474, or both. Thus, it appears that, in the absence of other known confounding genomic events, PIK3CA-H1047R mutation is more potent in activating AKT than PIK3CA-E545K mutation. These results reveal distinct AKT isoform-driven signaling/biology downstream of PIK3CA-E545K
and PIK3CA-H1047R mutation, which, to our knowledge, is not routinely considered while assessing the impact of PIK3CA aberration on cancer progression.
Deciphering PIK3CA-E545K:AKT isoform:ER signaling axis in MCF-7 cells.
One of our focuses was to determine how PIK3CA mutation and specific AKT isoform activation influence ER activity. MCF-7 cells are ideal for this purpose because these cells are ER-positive, E2-dependent, and contain PIK3CA-E545K mutation. A recent study demonstrated that PIK3CA-E545K mutation is responsible for AKT activity in MCF-7 cells (28). MCF10A, HMECs and their PIK3CA mutant derivatives are not ideal because these cells do not express ER and E2 treatment did not alter phosphorylation status of AKT1 or AKT2 in wild type or mutant MCF10A cells (data not shown). Since we observed an association between PIK3CA-E545K mutation and AKT1 activation in MCF-7, our goal was to further evaluate whether AKT1 integrates signaling from PIK3CA-E545K mutation to ER through AKT1 or AKT2. Towards this end, we generated cells expressing shRNA against AKT1 or AKT2 using previously validated shRNA constructs (20) (Figure 2A ). Interestingly, AKT1 knockdown in these cells resulted in compensatory increase in AKT2.
We first examined pAKT_pS473 levels in MCF-7pLKO, AKT1KD, and AKT2KD cells upon activation of PI3K by heregulin. Heregulin-mediated AKT activation was lower in AKT1KD cells compared with control pLKO or AKT2KD cells ( Figure 2B ). There are two possible explanations for the observed effects of AKT1 knockdown on heregulin-induced pAKT_pS473 levels; one is that heregulin preferentially activates AKT1 and the second is that AKT_pS473 antibody preferentially recognizes phosphorylated AKT1. To test these possibilities, we probed untreated and heregulin-treated MCF-7pLKO, AKT1KD and AKT2KD cells with AKT1_pS473 and AKT2_pS474 antibodies. As expected, heregulin-induced AKT1_pS473 levels were lower in AKT1KD cells ( Figure 2C ). Heregulin-induced AKT2 activation was unaffected in AKT1KD but reduced in AKT2KD cells. Therefore, lower levels of AKT_pS473 in heregulin-treated AKT1KD cells compared with pLKO or AKT2KD cells could be due to preferential recognition of phosphorylated AKT1 by this antibody. We consistently observed lower AKT1_pS473 levels in AKT2 knockdown cells suggesting a regulatory role for AKT2 in controlling AKT1 activity. Similar results were obtained when cells were stimulated with insulin; AKT1_pS473 levels were lower in insulin-treated AKT1KD and AKT2KD cells compared with pLKO cells ( Figure 2D ).
We performed two sets of experiments to link specific AKT isoforms to E2:ER signaling. First, we examined whether AKT1 and AKT2 isoforms control the expression of ER and pioneer factors that regulate ER (29) . AKT1 or AKT2 knockdown did not alter ER, GATA3, and FOXA1 levels. Basal expression of AP2 was lower in AKT1KD compared with pLKO or AKT2KD cells ( Figure 3A) . Among E2 inducible proteins tested, AKT1 or AKT2 knockdown had minimal effect on cMyc induction, whereas knockdown of either isoforms reduced E2-inducible Cyclin D1.
Second, we performed microarray analysis of untreated and 3-hours E2-treated cells. AKT2 knockdown had greater effect than AKT1 knockdown on basal expression of genes (2982 genes versus 893 genes out of 15704 genes at p-value of <0.01 in the array with measurable expression, p=0.0001, Chi-square with Yates correction) ( Table 1 ). In fact, AKT2 knockdown increased the basal expression of 2955 genes, which was significantly higher than the effect of AKT1 knockdown (656 genes, p=0.0001 AKT1 vs. AKT2). Thus, AKT2 potentially serves as a global suppressor of gene expression.
Alternatively, distinct role of AKT1 and AKT2 in cell cycle may have indirectly contributed to differences in basal gene expression between three cell types (30) . Names and fold-change in expression of genes along with ER binding pattern to these genes, determined based on previously described ChIP-seq or ChIP-on-Chip datasets, are presented in Table S2 . TFBS enrichment analysis of genes differentially expressed under With p<0.01, we found 1912 genes to be E2-regulated in pLKO cells with 1682 genes being induced. When the expression of these E2-regulated genes was analyzed after normalizing for basal expression in AKTKD cells, AKT1KD demonstrated higher effect than AKT2KD on E2-regulated gene expression (Table 1 and Table S3) To obtain insight into how AKT isoforms might differentially control the expression of E2 regulated genes, we assigned binding sites for ER, FOXA1, GATA3, p300, CBP, SRC1, SRC2, and SRC3 to each of the E2-regulated genes that were differentially affected by AKT isoforms (Table S3 ). Binding sites of these transcription co-regulators within 10-kB upstream of transcription start site and 5-kB downstream of the 3' end of E2-regulated genes in MCF-7 cells have been described (31) (32) (33) . Less than 5% of genes differentially expressed in both cell types contained binding sites for p300, CBP, or any of the SRCs (Table S3) . 50%, 60%, and 80% of differentially expressed genes contained ER, FOXA1, and GATA3 binding sites, respectively, with no AKTisoform-specific enrichment of binding sites.
Binding sites for the pioneer factors GATA3 and PBX1 were enriched in genes whose E2-dependent expression was affected in both AKT1KD and AKT2KD cells ( Figure 3C ). AP2, STAT5, and FOXO1 binding sites were enriched in genes that were dependent on AKT1 for E2-regulated expression ( Figure 3C ). By contrast, binding sites for NF-B and NKX2-5 were enriched in genes that were dependent on AKT2 ( Figure   3C ).
It is interesting that few of the transcription factors noted above have previously been shown to be E2-regulated and mediate secondary E2 response (34) . AKT isoform dependency of several of the E2-regulated genes could be due to differential influence of AKT1 and AKT2 isoforms on E2-dependent expression of these transcription factors.
Indeed, majority of these transcription factors including E2F family members are E2-regulated in our cell lines and AKT1 and AKT2 knockdown had differential effect on their E2-regulated expression ( Figure 3D ). Collectively, these results suggest that AKT isoforms differentially regulate primary and secondary E2-response genes.
Cyclin D1, in addition to being E2-inducible, interacts with ER and influences the expression of >2000 E2-regulated genes (35) . We analyzed the effect of AKT isoform knockdown on top 50 of Cyclin D1-ER-regulated genes. Out of 38 genes that overlapped between Cyclin D1-ER and AKT-isoform-ER datasets, E2-regulated expression of only two genes intersected with Cyclin D1-ER and AKT1-ER axis (MSMB and IL17RB, Table S3 ) and none with AKT2. Thus, AKT isoforms appears to have minimum role in regulating Cyclin D1-ER axis.
Identification of PIK3CA-E545K:AKT1:ER:E2 gene expression signature.
Among the pioneer factors that control ER:E2-mediated gene expression, prognostic utility of E2:ER:FOXA1 and E2:ER:PBX1 regulated genes has been described (23). FOXA1-E2 regulated genes are associated with good outcome whereas PBX1-E2 regulated genes are associated with poor outcome. We restricted our analysis to genes of these signatures and determined the influence of AKT1 and AKT2 on their expression. Neither AKT1 nor AKT2 had an influence on PBX1-E2 gene expression signature. By contrast, FOXA1-E2 dependent genes were preferentially associated with AKT1 (p<7.9 10 -9 and Odd ratio 17.7) (Table S4) .
To determine the influence of E2-regulated genes that are additionally controlled by AKT1 (called FOXA1-E2-AKT1 signature hereafter), we analyzed the impact of FOXA1-E2-AKT1 signature in the publicly available dataset, which allowed a combined analysis of tumors of 2977 patients (25) . Data for CXCL12, PLAC1, SGK1, SLC22A5, and TGM2 were available in this database and all of them were positively regulated by AKT1. Elevated expression of genes in the signature was associated with better recurrence-free survival in luminal A and luminal B breast cancer ( Figure 3E ). This signature had similar effect on outcome in patients treated with endocrine therapy, tamoxifen therapy, or surgery alone ( Figure 3E ). Also, the signature predicted better distant metastasis-free survival in patients with luminal A, luminal B breast cancers, and patients who did not receive systemic therapy ( Figure 3E ). Thus, FOXA1-E2-AKT1 signature likely defines a cancer type with robust hormone receptor activity.
We independently validated the above results using a resource developed by our group (26). In Wang et al dataset (36) , elevated expression of this signature was associated with favorable recurrence-free survival among patients with ER-positive breast cancer ( Figure S3 ). In the Loi et al dataset (37) , elevated expression of this signature was associated with better outcome in tamoxifen-treated patients. In the TCGA dataset, elevated expression of this signature was associated with favorable overall survival of patients with PR-positive and a trend in ER-positive breast cancer.
We performed additional analysis to find a relationship between genes differentially influenced by AKT1 or AKT2 under basal or E2-treated condition and various other ER-positive breast cancer-specific prognostic signatures including SRC-1, SRC-2, SRC-3, p300, CBP (32), and tamoxifen resistance signatures (38) . AKT1 or AKT2 knockdown had minimum effect on the expression of genes in these signatures.
Thus, the signature identified above is unique to AKT1 and is not related to other signatures of ER-positive breast cancer.
Recent studies have described an ER-dependent E2F-mediated resistance to aromatase inhibitors (39) . Our array contained detectable expression of 17 out of the 24 genes of this signature. Nine of these genes at p<0.01 were E2 inducible (Table S4) .
Seven of these genes lost E2 inducible expression in AKT1KD or AKT2KD cells. Thus, AKT influences the expression of genes associated with anti-estrogen resistance, although the effects are not isoform-specific.
Validation of E2-regulated genes that are differentially influenced by AKT1 and AKT2 in MCF-7 cells.
We Figure   4B ). These results further confirm the ability of AKT1 and AKT2 to distinctly modulate E2-regulated gene expression.
AKT1 influences response of MCF-7 cells to E2 and PI3K inhibitors.
We next examined the effect of AKT1 and AKT2 knockdown on E2-stimulated proliferation. Early passage AKT1KD cells demonstrated least E2-stimulated proliferation ( Figure 5A ). However, AKT knockdown cells remained as sensitive as pLKO cells to tamoxifen ( Figure 5B ).
We next tested whether AKT1 isoforms have specific role in determining sensitivity to PI3K-specific inhibitor BYL719, pan-PI3K inhibitor BKM120, PI3K/mTOR dual inhibitor NVP-BEZ235, and pan-AKT inhibitor MK2206. AKT1 levels determined sensitivity to BYL719, as AKT1KD cells were resistant to this drug compared with pLKO or AKT2KD cells (for example, 20% survival of pLKO cells compared with 80% survival of AKT1KD cells when treated with 100 nM drug, Figure   5B ). Interestingly, E2 treatment significantly reduced sensitivity to this drug irrespective of AKT isoform knockdown suggesting the existence of E2:ER-dependent resistance mechanism to this class of inhibitors. AKT1KD cells demonstrated a modest increase in sensitivity to BKM120 under basal growth condition but the sensitivity was reversed upon E2 addition ( Figure 5C ). AKT1 and AKT2 knockdown had statistically significant effects on sensitivity to NVP-BEZ235 and MK2206 but the effects were numerically modest ( Figure 5D and E). AKT2KD cells showed resistance to MK2206 under E2 treated condition ( Figure 5E ). These results indicate that AKT1 has significant influence on sensitivity to PI3K-specific inhibitors compared with AKT2.
AKT isoforms are not essential for E2 response in BT-474 cells.
To determine whether AKT1:ER signaling axis extends beyond MCF-7 cells, we examined the role of AKT1 and AKT2 in E2 and PI3K inhibitor response in BT-474
with PIK3CA-K111N mutation and HER2 amplification. In these cells, knockdown of both AKT1 and AKT2 reduced heregulin-induced AKT1_pS473 levels ( Figure 6A ). By contrast, unlike in MCF-7 cells, AKT1 knockdown reduced heregulin-induced AKT2_pS474 levels. Thus, type of crosstalk between AKT isoforms is cell type-specific.
Unlike in MCF-7 cells, where AKT1 and AKT2 knockdown did not reproducibly affect basal proliferation (data not shown), knockdown of both isoforms of AKT reduced basal proliferation but not E2-inducible proliferation of BT-474 cells ( Figure 6B and C).
Consistent with the limited role of AKT isoforms in E2-mediated proliferation, E2-induced SIAH2 expression was unaffected by either AKT1 or AKT2 knockdown in these cells ( Figure 6D ). With respect to PIK3CA/mTOR inhibitor response, BT-474 cells were not sensitive to BYL719 (data not shown). However, these cells were sensitive to NVP-BEZ235 ( Figure 6E ). Interestingly, AKT1KD and AKT2KD cells showed partial resistance to this drug, although statistical significance was achieved only in AKT2KD cells. Thus, AKT inhibition may force BT-474 cells to adapt to alternative survival mechanism independent of PI3K signaling.
Discussion
Discovery of recurrent activating mutation of PIK3CA in a variety of cancers has prompted the development of PI3K inhibitors as cancer therapeutics (42, 43) . Response to these inhibitors has not always been correlated with PIK3CA mutations suggesting that additional pathways control therapeutic response. In this regard, Myc, eIF4E, RSK3/4
and JAK/STAT pathways are suggested to be involved in conferring resistance to these inhibitors (1). Our results show significant cell type specificity in AKT isoform activation upon PIK3CA mutation and the unique ability of activated AKT1 downstream of PIK3CA-E545K mutation in determining E2 response and sensitivity to PI3K inhibitors.
Recently developed antibodies against activated AKT1 and AKT2 allowed us to make major stride in defining the role of AKT isoforms in the context of PIK3CA mutation. We observed cell type-specific differences in basal levels of activated AKT1
and AKT2 suggesting that genomic aberrations can lead to biased activation of these isoforms. These reagents allowed us to reexamine one of the earlier observations regarding basal AKT activity in breast cancer cell lines with PIK3CA mutation. For example, MCF-7 cells, despite containing PIK3CA-E545K mutation, were reported to lack activated AKT based on western blot analysis with AKT_pS473 antibody (27) .
However, we detected AKT1_pS473 in these cells.
Cell type specific role of AKT isoforms in E2 signaling. In BT-474 cells with distinct PIK3CA mutation and HER2 amplification, AKT isoforms were not required for E2 response ( Figure 6 ). Alternative signaling pathway activation due to HER2 amplification may have rendered AKT isoforms redundant for ER signaling in these cells. HER2 can activate MAPKs, which can also increase ER activity (44) . Therefore, multiple genomic aberrations need to be taken into consideration before concluding whether mutant PIK3CA integrates with ER signaling through AKT isoforms.
The mechanisms leading to preferential engagement of AKT1 over AKT2 in eliciting optimal E2 response in MCF-7 cells are unknown. Both AKT1 and AKT2 phosphorylate ER; therefore, difference in ER phosphorylation is less likely to account for differential effects on E2 signaling (7, 45) . AKT1 and AKT2 share common upstream activators but frequently target distinct downstream molecules such as EMSY and Palladin (20, 46) . Therefore, a likely scenario includes specific engagement of AKT1
with ER co-regulatory molecules, histone modifying enzymes, or pioneer factors. We Clinically, tumors with active AKT1 and ER signaling may show higher sensitivity to PI3K inhibitors. However, developing markers of sensitivity to these drugs may prove difficult because of cell type specificity observed in the effects of PIK3CA mutation on signaling by AKT isoforms. Nonetheless, focused analyses of PIK3CA-E545K-AKT1-ER signaling axis may be useful in select number of cases. AKT1 knockdown cells showed similar trend (p=0.06).
